NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient ...(lysis population resides within 60 miles...)

In compiling the survival and kidney transplant analysis, NxStage captured mortality data from 2,553 patients using the NxStage System One, from over 300 dialysis centers, totaling 1,603 patient years of experience. This data was then compared to mortality rates reported in the United States Renal Data System for 2007 using a Standard Mortality Ratio (SMR) methodology, adjusting for patient age and gender.

According to Dr. Alan Hull, Chief Medical Advisor of NxStage Medical, "With its unique leadership position in the growing home daily hemodialysis movement, NxStage has a commitment to share data and insight gleaned from continuing use of this therapy with patients, physicians and providers. The information that NxStage is making available, while not derived from a controlled study, provides a current, accurate picture of who is participating in daily home hemodialysis and a longitudinal view of the clinical outcome trends emerging from the growing use of this therapy. We will continue to enhance collective knowledge about the use of daily home hemodialysis via ongoing access to our database, which will be updated on at least a semi-annual basis, as well as our concurrent efforts to definitively establish long term outcomes via initiatives such as our FREEDOM Study."

The growth of NxStage therapy in the three years since its FDA clearance for home use has led to a more than doubling of the number of patients experiencing the potential benefits of home hemodialysis.

"NxStage was founded on our belief in the clinical benefits of daily home hemodialysis for patients with ESRD," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "It is gratifying to see these benefits experienced b
'/>"/>